Is BLOOD CREATININE INCREASED a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed BLOOD CREATININE INCREASED.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 22 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported BLOOD CREATININE INCREASED to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and BLOOD CREATININE INCREASED. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause BLOOD CREATININE INCREASED, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes BLOOD CREATININE INCREASED. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if BLOOD CREATININE INCREASED ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing BLOOD CREATININE INCREASED: 22
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where BLOOD CREATININE INCREASED is a reported side effect: 0.6609%

FDA reports of any drug causing BLOOD CREATININE INCREASED : 27976
Average percentage for all medicated patients where BLOOD CREATININE INCREASED is reported as a complication: 0.1753%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
TONSIL CANCER ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with BLOOD CREATININE INCREASED:

ASPIRIN (3159 patients)
LASIX (2205 patients)
NEORAL (1867 patients)
FUROSEMIDE (1709 patients)
ZOMETA (1594 patients)
PREDNISOLONE (1553 patients)
ALLOPURINOL (1346 patients)
EXJADE (1321 patients)
PREDNISONE (1316 patients)
CYCLOSPORINE (1236 patients)
LISINOPRIL (1170 patients)
LIPITOR (1167 patients)
OMEPRAZOLE (1086 patients)
DIOVAN (1084 patients)
MYCOPHENOLATE MOFETIL (1053 patients)
NORVASC (1038 patients)
SIMVASTATIN (1019 patients)
ACETAMINOPHEN (935 patients)
ATENOLOL (922 patients)
VIOXX (802 patients)
HYDROCHLOROTHIAZIDE (786 patients)
DEXAMETHASONE (776 patients)
AMLODIPINE (761 patients)
DIGOXIN (751 patients)
FOLIC ACID (732 patients)
AREDIA (720 patients)
GLEEVEC (717 patients)
COUMADIN (698 patients)
METFORMIN HCL (689 patients)
SPIRONOLACTONE (684 patients)
WARFARIN SODIUM (676 patients)
ZOCOR (673 patients)
TACROLIMUS (667 patients)
CISPLATIN (659 patients)
LEVOTHYROXINE SODIUM (654 patients)
PLAVIX (644 patients)
METHOTREXATE (639 patients)
PROGRAF (639 patients)
REVLIMID (622 patients)
RAMIPRIL (621 patients)
FOSAMAX (608 patients)
CRESTOR (594 patients)
POTASSIUM CHLORIDE (582 patients)
VALTREX (571 patients)
CELLCEPT (570 patients)
NEXIUM (553 patients)
ALDACTONE (548 patients)
INSULIN (544 patients)
SYNTHROID (535 patients)
PREDNISONE TAB (534 patients)
ENALAPRIL MALEATE (532 patients)
METOPROLOL TARTRATE (531 patients)
IBUPROFEN (522 patients)
NEURONTIN (522 patients)
LANTUS (491 patients)
VANCOMYCIN (484 patients)
PRILOSEC (471 patients)
ACYCLOVIR (468 patients)
VOLTAREN (465 patients)
LYRICA (464 patients)
LANSOPRAZOLE (460 patients)
LORAZEPAM (458 patients)
TOPROL-XL (457 patients)
SANDIMMUNE (449 patients)
CARVEDILOL (448 patients)
OXYCONTIN (433 patients)
VELCADE (429 patients)
CERTICAN (425 patients)
BACTRIM (416 patients)
FLUOROURACIL (413 patients)
VITAMIN D (412 patients)
DECADRON (398 patients)
PROTONIX (397 patients)
GABAPENTIN (392 patients)
MYFORTIC (390 patients)
METHYLPREDNISOLONE (384 patients)
RAPAMUNE (384 patients)
METOPROLOL (383 patients)
CYCLOPHOSPHAMIDE (383 patients)
LOVENOX (379 patients)
ALBUTEROL (376 patients)
ZOFRAN (363 patients)
AMBIEN (360 patients)
FAMOTIDINE (360 patients)
ALTACE (352 patients)
TORSEMIDE (352 patients)
CELEBREX (345 patients)
ARANESP (343 patients)
GLYBURIDE (337 patients)
MULTAQ (334 patients)
CARBOPLATIN (330 patients)
COZAAR (329 patients)
CIPROFLOXACIN (328 patients)
FLUCONAZOLE (328 patients)
RASILEZ (326 patients)
HEPARIN (321 patients)
BYETTA (319 patients)
HUMIRA (318 patients)
REBETOL (318 patients)
ZANTAC (311 patients)
MORPHINE (307 patients)
ATIVAN (303 patients)
METOPROLOL SUCCINATE (300 patients)
SIMULECT (300 patients)
MAGNESIUM OXIDE (298 patients)
CALCIUM (297 patients)
AMLODIPINE BESYLATE (295 patients)
CALCIUM CARBONATE (293 patients)
ACTOS (291 patients)
COREG (290 patients)
OXYCODONE HCL (289 patients)
PREDONINE (287 patients)
RANITIDINE (287 patients)
NIFEDIPINE (286 patients)
ATORVASTATIN CALCIUM (285 patients)
AMARYL (284 patients)
PERCOCET (284 patients)
LOXONIN (283 patients)
MICARDIS (282 patients)
METFORMIN (282 patients)
BISOPROLOL FUMARATE (281 patients)
AZATHIOPRINE (281 patients)
ZOLOFT (279 patients)
CLOZARIL (279 patients)
PREVACID (279 patients)
VICODIN (279 patients)
PAXIL (276 patients)
TRAMADOL HCL (274 patients)
AVASTIN (274 patients)
XANAX (271 patients)
PANTOPRAZOLE (271 patients)
FERROUS SULFATE TAB (269 patients)
SEROQUEL (268 patients)
GLIPIZIDE (266 patients)
CLONIDINE (265 patients)
TAXOTERE (265 patients)
SIROLIMUS (264 patients)
ZETIA (263 patients)
AFINITOR (260 patients)
LEVAQUIN (258 patients)
GLUCOPHAGE (253 patients)
ICL670A ICL+DISTAB (253 patients)
SUTENT (253 patients)
DIFLUCAN (251 patients)
REMICADE (251 patients)
THALIDOMIDE (250 patients)
TEGRETOL (249 patients)
VALSARTAN (248 patients)
LEVOFLOXACIN (248 patients)
AMIODARONE HCL (243 patients)
JANUVIA (243 patients)
PEPCID (242 patients)
RIBAVIRIN (237 patients)
NITROGLYCERIN (236 patients)
PANTOPRAZOLE SODIUM (235 patients)
ZOVIRAX (233 patients)
CLOZAPINE (233 patients)
PROCRIT (230 patients)
TELAVIC (TELAPREVIR) (230 patients)
METOCLOPRAMIDE (230 patients)
ZYPREXA (229 patients)
FLOMAX (227 patients)
HUMALOG (226 patients)
MULTI-VITAMINS (225 patients)
MORPHINE SULFATE (222 patients)
ADALAT (222 patients)
CYTARABINE (220 patients)
DICLOFENAC SODIUM (219 patients)
FENTANYL (219 patients)
TRICOR (216 patients)
VIREAD (215 patients)
CLONAZEPAM (213 patients)
LACTULOSE (212 patients)
DOXAZOSIN MESYLATE (212 patients)
MUCOSTA (211 patients)
HERCEPTIN (211 patients)
ACETYLSALICYLIC ACID SRT (209 patients)
CANDESARTAN CILEXETIL (207 patients)
THYMOGLOBULIN (207 patients)
ATACAND (207 patients)
NYSTATIN (206 patients)
SOLU-MEDROL (205 patients)
LEXAPRO (204 patients)
SPIRIVA (204 patients)
ADVAIR DISKUS 100/50 (203 patients)
TAXOL (203 patients)
PRAVASTATIN (203 patients)
DURAGESIC-100 (202 patients)
LITHIUM CARBONATE (202 patients)
CLARITHROMYCIN (201 patients)
CITALOPRAM HYDROBROMIDE (199 patients)
BEVACIZUMAB (199 patients)
COLACE (196 patients)
DIAZEPAM (195 patients)
ETOPOSIDE (193 patients)
AVANDIA (193 patients)
OXALIPLATIN (191 patients)
ALPRAZOLAM (190 patients)
LOPRESSOR (190 patients)
NEXAVAR (187 patients)
EPOGEN (186 patients)
GEMZAR (186 patients)
TAKEPRON (184 patients)
FEMARA (183 patients)
AMITRIPTYLINE HCL (183 patients)
COMPAZINE (182 patients)
TASIGNA (181 patients)
TENORMIN (181 patients)
VITAMIN B-12 (181 patients)
IRBESARTAN (181 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about BLOOD CREATININE INCREASED and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.